Table 3 Clinicopathological characteristics of breast cancers with and without pathogenic mutations
Variable | Pathogenic N = 17 | No Pathogenic N = 47 | No. of all | P value |
|---|---|---|---|---|
Age | ||||
< 40 years | 7 (41.2%) | 7 (14.9%) | 14 (21.9%) | 0.039 |
≥ 40 years | 10 (58.8%) | 40 (85.1%) | 50 (78.1%) | |
Histopathological type | ||||
Ductal carcinoma in situ | 1 (5.9%) | 7 (14.9%) | 8(12.5%) | 0.434 |
Invasive ductal carcinoma | 16 (94.1%) | 40 (85.1%) | 56 (87.5%) | |
Tumor size | ||||
T1 | 8 (47.1) | 15 (31.9) | 23 (35.9) | 0.534 |
T2 | 7(41.2) | 26 (55.3) | 33 (51.6) | |
T3 | 2 (11.8) | 6 (12.8) | 8 (12.5) | |
Node metastasis | ||||
N- | 10 (58.8) | 34 (72.3) | 44 (68.8) | 0.365 |
N + | 7 (41.2) | 13 (27.7) | 20 (31.2) | |
Recurrence or Metastasis | ||||
Yes | 5 (29.4) | 3 (6.4) | 8 (12.5) | 0.014 |
No | 12 (70.6) | 44 (93.6) | 56 (87.5) | |
Biologic feature | ||||
unfavorable | 10(58.8) | 6(12.8) | 16(25.0) | 0.000 |
Intermediate/ favorable | 7(41.2) | 41(87.2) | 48(75.0) | |
Nuclear grade | ||||
Low/Intermediate | 11 (64.7) | 43(91.5) | 54 (84.4) | 0.017 |
high | 6 (35.3) | 4 (8.5) | 10(15.6) | |
ER | ||||
ER- | 10 (58.8) | 9(19.1) | 19 (29.7) | 0.004 |
ER + | 7 (41.2) | 38 (80.9) | 45 (70.3) | |
PR | ||||
PR- | 10(58.8) | 10(21.3) | 20(31.2) | 0.007 |
PR + | 7(41.2) | 37 (78.7) | 44 (68.8) | |
HER2 | ||||
HER2- | 13 (76.5) | 29 (61.7) | 42 (65.6) | 0.375 |
HER2 + | 4 (23.5) | 18 (38.3) | 22 (34.4) | |
p53 | ||||
p53- | 5 (29.4) | 24 (51.1) | 29 (45.3) | 0.160 |
p53 + | 12 (70.6) | 23 (48.9) | 35 (54.7) | |
Ki67 | ||||
Ki67- | 1 (5.9) | 13 (27.7) | 14 (21.9) | 0.057 |
Ki67 + | 16 (94.1) | 34 (72.3) | 50 (78.1) | |
Molecular subtype | ||||
Luminal A | 3 (17.6) | 15 (31.9) | 18 (28.1) | |
Luminal B | 5 (29.5) | 24 (51.1) | 29 (45.3) | 0.000 |
HER2 over-expression | 0 (0.0) | 5 (10.6) | 5 (7.8) | |
Triple negative | 9 (52.9) | 3 (6.4) | 12 (18.8) | |
Triple negative | ||||
No | 8 (47.1) | 44 (93.6) | 52 (81.2) | 0.000 |
Yes | 9 (52.9) | 3 (6.4) | 12 (18.8) | |